Cite

HARVARD Citation

    Ellwanger, K. et al. (n.d.). EGFRvIII TandAbs are specific and highly potent drug candidates for the treatment of solid tumors. Journal for immunotherapy of cancer. p. . [Online]. 
  
Back to record